To analyze the mechanistic correlates of disease control in the context of ICI plus IC combination therapies, we quantified activation and effector markers within CD8+ T cells as well as Treg abundance in CT26 tumor-bearing mice treated with ICIs alone, Y33 IC alone, and ICIs plus either Y33 IC or Control IC (figure 6A). The gene discussed is DDX53; the disease is neoplasm.